Phospho-MET immunoassays demonstrate statistically relevant changes (±SEM) in target at a 25 mg/kg dose of PF02341066. Surrogate for biological variation (shaded area) in phospho-MET assays were defined as follows: Biological variance = 1.96 × √2 × √(Vw)2 + (Va)2, where Vw is the average variation (CV) in vehicle-treated groups in Study 2 (PF02341066) and Va is the analytical variance (CV).
MET (cMet) proto-oncogene is a receptor tyrosine kinase that is normally activated through binding to hepatocyte growth factor (HGF). HGF-MET signaling plays a critical role in regulating tumor oncogenic processes, such as mitogenesis, survival, and invasive growth, especially in the metastatic process.
Several selective kinase inhibitors targeting MET are currently under clinical investigation. To support and guide the clinical investigations of MET inhibitors, we describe the development of pharmacodynamic (PD) assays to assess MET modulation.
MET has multiple phosphorylation sites that can potentially be modified by the candidate compounds. We focused on developing assays to two critical domains in MET activation: 1) the tyrosine kinase catalytic (TK) domain; and 2) the multifunctional docking site (Fig. 1) Phosphorylation at the TK domain (Y1234 and Y1235) regulates the catalytic activity. Phosphorylation of Y1349 and Y1356 (multifunctional docking site) results in the binding of adaptor proteins, such as Gab-1, Grb2, Shc, and c-Cbl, and the subsequent activation of signal transducers, such as PI3K, PLC-y, STATs, ERK 1 and 2, and FAK.
MET Immunoassays. Rabbit monoclonal antibodies specific to MET, phosphorylated at Y1235 (no reactivity to Y1234) and Y1356, were generated to measure the phosphorylation status of intact MET. Intact full-length MET was purified from the membrane fraction of HEK293 cells expressing recombinant wild-type human MET (amino acids 1-1390). Antibodies against phospho-MET were combined with an N-terminal-specific capture antibody to develop ELISA (Fig. 2 ).
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All animals used in this research project were cared for and used humanely according to the following policies: the U.S. Public Health Service Policy on Humane Care and Use of Animals (2000); the Guide for the Care Fig. 3 (n=5-6 per group/dose/time point). Tumors were resected and processed into lysates by homogenization. All comparisons between vehicle-and drug-treated groups were performed using two-tailed unpaired students t-test (p-values ≤0.05 were considered statistically significant). Inter-Assay CV (n) <15% (5) <15% (5) <15% (6) Intra-Assay CV (n) <10% (22) <10% (21) <10% (12) Dilution Recovery* 99%±12% 103%±12% 99%±11%
Treatment and Sampling Schedule
Spike Recovery* 98%±18% 88%±5% 86%±29%
Results

Methods
Efficacy of MET Inhibitors We describe the development and analytical validation of novel phospho-MET PD assays. We have demonstrated the fit-for-purpose utility of phospho-MET assays to study the PD modulation of MET in tumor biopsies. MET PD assays are robust, accurate, sufficiently sensitive to quantify MET in tumor samples, and demonstrate target modulation using two potent MET inhibitors, PHA665752 and PF02341066, in relevant xenograft tumor models. Both phospho-Y1235 MET and phospho-Y1356 MET assays showed 70%-80% inhibition of phosphorylation within 4 h at most effective doses. The time course of Y1235 and Y1356 MET phosphorylation showed a sustained response. Inhibition of phospho-MET appears to correlate to the antitumor activity of MET inhibitors. The results of this study support the usefulness of MET assays for the PD evaluation of MET inhibitors in clinical investigations. 
